ICT-1402

ICT-1402 is a preclinical drug candidate developed by InnoCure Therapeutics for the treatment of NUT midline carcinoma (NMC), a rare and aggressive form of cancer. The drug is developed using InnoCure's proprietary targeted protein degradation (TPD) technology, which includes PROTAC (Proteolysis-Targeting Chimera) and MILPROTAC platforms. These modalities are designed to selectively eliminate disease-driving proteins by hijacking the cell's internal ubiquitin-proteasome system, potentially addressing targets previously considered 'undruggable.' ICT-1402 was featured at the BioCentury Grand Rounds R&D Conference in 2024. While its specific molecular target has not been publicly disclosed, the program is part of InnoCure's focus on novel oncology and rare disease therapeutics.